Emergent BioSolutions related Press Releases

Emergent BioSolutions Announces Commencement of Phase I/II Clinical Trial of Anthrax Immune Globulin for Treating Anthrax Disease ROCKVILLE, Md., Mar 17, 2009 (BUSINESS WIRE) ----Emergent

... Read more...

Emergent BioSolutions Ends $78 Million Deal to Acquire Protein Sciences January 2, 2009 ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS - News) announced today that it has

... Read more...

U.S. Government Issues Declaration Covering Emergent BioSolutions' BioThrax® and Anthrax Immune Globulin under Prep Act HHS Secretary Determines That Potential Threat of Exposure to Anthrax... Read more...

Emergent BioSolutions Signs Contract with BARDA/NIAID, Valued at Up to $29.7 Million, to Fund Development of AV7909 - A Next Generation Anthrax Vaccine --AV7909 Contract is in Addition to Recently... Read more...

Emergent BioSolutions Receives $24 Million Development Contract from the Department of Health and Human Services to Fund Continued Development of Anthrax Monoclonal Antibody ROCKVILLE,... Read more...

U.S. Department of Health and Human Services Remains Committed to Procurement of BioThrax Under Current Contract ROCKVILLE, Md. -- Nov. 19, 2007--Emergent BioSolutions Inc. (NYSE:EBS) announced... Read more...

Emergent BioSolutions Signs $448 Million Three Year Contract with Department of Health and Human Services Emergent BioSolutions, announced today that it has signed a three year contract with the... Read more...